<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00707525</url>
  </required_header>
  <id_info>
    <org_study_id>0607-C-M09-EL</org_study_id>
    <nct_id>NCT00707525</nct_id>
  </id_info>
  <brief_title>Embryo Aneuploidies and Ovarian Stimulation</brief_title>
  <official_title>Incidence of EmbyoO Aneuploidies in Natural Versus Stimulated Cycles in the Same Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a considerable concern about the effects of controlled ovarian hyperstimulation
      (COH) for In Vitro Fertilization- Embryo Transfer (IVF-ET) on embryo quality and on the
      incidence of chromosomal abnormalities in oocytes and embryos.

      The main question remaining is if COH may increase the aneuploidies rate in young and healthy
      women. Therefore, the primary endpoint of the present study is to analyse the incidence of
      chromosomal abnormalities in this group of patients (oocyte donors), either in oocytes
      obtained after a natural cycle or in those retrieved after a COH cycle. To get rid of the
      male factor influence, donated sperm will be used.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Embryo aneuploidies</measure>
    <time_frame>2 cycles</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <condition>Embryo Aneuploidies</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Natural cycle oocyte donation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stimulated cycle oocyte donation.
Long protocol down-regulation with a GnRH agonist, starting on the midluteal phase of the previous cycle with leuprolide acetate (0.2mg/day).
Once evidence of downregulation is documented, leuprolide will be halved to 0.1 mg daily.
COH with be carried on with gonadotropins (150UI/day of rFSH and 75 UI/day of HP-hMG). The dose can be adjusted according to ovarian response as judged by ultrasound and by serum oestradiol (E 2 ) concentrations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Preimplantation Genetic Diagnosis</intervention_name>
    <description>Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Donor Inclusion Criteria:

          -  18 to 35 years old.

          -  BMI: 18-25Kg/m2

          -  Regular menstrual cycles

          -  Normal kariotype

          -  No previous controlled ovarian hyperstimulation (COH) treatments.

        Donor Exclusion Criteria:

          -  Endometriosis

          -  Policystic ovarian syndrome

          -  Recurrent miscarriages.

        Recipient Inclusion Criteria

          -  Aged until 45 years old

          -  No systemic diseases

          -  Following egg and sperm donation treatment.

        Recipient exclusion criteria:

          -  Uterine disease (polyps, myomas, mullerian defects)

          -  Recurrent miscarriages.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Valenciano de Infertilidad</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2008</study_first_submitted>
  <study_first_submitted_qc>June 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2008</study_first_posted>
  <last_update_submitted>March 25, 2010</last_update_submitted>
  <last_update_submitted_qc>March 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Elena Labarta</name_title>
    <organization>Instituto Valenciano de Infertilidad, Spain</organization>
  </responsible_party>
  <keyword>aneuploidies, natural cycle, stimulated cycle, preimplantation genetic diagnosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aneuploidy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

